Icosavax: AstraZeneca to buy vaccine company for $1.1B
AstraZeneca has entered a definitive agreement to acquire Icosavax for $1.1 billion, the drugmaker said Dec. 12.
Read full article »
Icosavax is a Washington-based biotechnology company that researches and develops VLP vaccines for the treatment of respiratory diseases.
Read more